glp-1 dual agonist Mechanisms of action of RA and GLP-1/GIP agonists. ↑: Main physiological actions of the

Although these drugs demonstrated effectiveness in improving blood sugar control and promoting weight loss, lawsuits now allege that GLP-1 receptor agonists may also be associated with severe gastrointestinal injuries, optic nerve complications, and other serious adverse health effects

Researchers are asking why There is mounting evidence to suggest GLP-1 obesity treatments also help reduce cancer risk, according to several recent studies

Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis

GLP-1 drugs help people lose weight, which is important because the risks from obesity account for 40% of all cancer diagnoses in the U.S., impacting prognosis and survival

Dual GLP-1/GIP receptor agonists (molecules engineered to simultaneously activate GLP-1R and GIPR) represent a pharmacological leap beyond classical incretin-based therapies

The team included BBRF Scientific Council member Nora Volkow, M.D., a leading expert on addiction who is director of the NIHs National Institute on Drug Abuse (NIDA)